BLCAP Mouse monoclonal Antibody IgG2a
Fig1: Western blot analysis of BLCAP on recombinant protein tissue lysate using anti-BLCAP antibody at 1/5,000 dilution.
Fig2: ICC staining BLCAP (green) in HepG2 cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Fig3: Immunohistochemical analysis of paraffin-embedded human breast tissue using anti-BLCAP antibody. Counter stained with hematoxylin.
Host Species; Species ReactivityMouse; Human, Rat
Application SummaryWB, IHC, ICC
Purification; FormulationProG affinity purified; 1*TBS (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesBladder cancer-associated protein, Bladder cancer 10 kDa protein
BackgroundBLCAP is a highly conversed gene with two exons and an intron encoding a 10kDa protein, which was originally identified from invasive bladder carcinoma in 2002. BLCAP is subject to adenosine to inosine (A-to-I) RNA editing. A-to-I RNA editing is an important post-transcription modification of RNA sequence, generating a diversity of RNA products different from the original DNA sequence. The adenosine deaminase acting on double-stranded RNA (ADAR) family of enzymes catalyze the conversion of adenosine (A) to inosine (I) in the double stranded RNA, and inosine is finally recognized as guanosine (G) in the process of mRNA translation. May regulate cell proliferation and coordinate apoptosis and cell cycle progression via a novel mechanism independent of both p53/TP53 and NF-kappa-B.(M1701-10)